Linked Life Data

9857976

Source:http://linkedlifedata.com/resource/pubmed/id/9857976

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
6
pubmed:dateCreated
1999-2-25
pubmed:abstractText
Depression with psychotic features has been shown to respond to selective serotonin reuptake inhibitors (SSRIs). The serotonin transporter (5-HTT) is a prime target for SSRIs. A functional polymorphism within the promoter region of the 5-HTT gene, leading to different transcriptional efficiency, was recently reported. We tested the hypothesis that allelic variation of the 5-HTT promoter could be related to the antidepressant response to fluvoxamine and/or augmentation with pindolol (a serotonin autoreceptors antagonist) which has been suggested as an augmentation therapy for nonresponders. One hundred and two inpatients with major depression with psychotic features were randomly assigned to treatment with a fixed dose of fluvoxamine and either placebo or pindolol for 6 weeks. Depression severity was assessed once a week using the Hamilton Depression Rating Scale. Allelic variation in each subject was determined using a PCR-based method. Data were analyzed with a three-way repeated measures analysis of variance. Both homozygotes for the long variant (l/l) of the 5-HTT promoter and heterozygotes (l/s) showed a better response to fluvoxamine than homozygotes for the short variant (s/s). In the group treated with fluvoxamine plus pindolol all the genotypes acted like l/l treated with fluvoxamine alone. Fluvoxamine efficacy in delusional depression seems to be related to allelic variation within the promoter of the 5-HTT gene. Even though other factors may be implicated, genotyping at 5-HTT promoter may represent a promising tool to individualize the pharmacological treatment of depression.
pubmed:commentsCorrections
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Nov
pubmed:issn
1359-4184
pubmed:author
pubmed:issnType
Print
pubmed:volume
3
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
508-11
pubmed:dateRevised
2008-11-21
pubmed:meshHeading
pubmed-meshheading:9857976-Antidepressive Agents, Second-Generation, pubmed-meshheading:9857976-Carrier Proteins, pubmed-meshheading:9857976-Depressive Disorder, pubmed-meshheading:9857976-Drug Therapy, Combination, pubmed-meshheading:9857976-Female, pubmed-meshheading:9857976-Fluvoxamine, pubmed-meshheading:9857976-Genotype, pubmed-meshheading:9857976-Humans, pubmed-meshheading:9857976-Male, pubmed-meshheading:9857976-Membrane Glycoproteins, pubmed-meshheading:9857976-Membrane Transport Proteins, pubmed-meshheading:9857976-Middle Aged, pubmed-meshheading:9857976-Nerve Tissue Proteins, pubmed-meshheading:9857976-Pindolol, pubmed-meshheading:9857976-Polymorphism, Genetic, pubmed-meshheading:9857976-Predictive Value of Tests, pubmed-meshheading:9857976-Promoter Regions, Genetic, pubmed-meshheading:9857976-Serotonin Antagonists, pubmed-meshheading:9857976-Serotonin Plasma Membrane Transport Proteins
pubmed:year
1998
pubmed:articleTitle
Polymorphism within the promoter of the serotonin transporter gene and antidepressant efficacy of fluvoxamine.
pubmed:affiliation
Istituto Scientifico Ospedale San Raffaele, Department of Neuropsychiatric Sciences, and Università di Milano, School of Medicine, Italy.
pubmed:publicationType
Journal Article, Clinical Trial, Comparative Study, Randomized Controlled Trial